- Home
- IMTX vs OLMA Comparison
IMTX vs OLMA Comparison
Compare IMTX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | OLMA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Germany | United States |
| Employees | 407 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMTX | OLMA |
|---|---|---|
| Price | $11.47 | $13.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $19.00 | ★ $44.89 |
| AVG Volume (30 Days) | 454.9K | ★ 877.5K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $3.89 |
| 52 Week High | $12.41 | $36.26 |
Technical Indicators
Market Signals| Indicator | IMTX | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 39.66 |
| Support Level | $9.24 | $13.54 |
| Resistance Level | $12.41 | $17.23 |
| Average True Range (ATR) | 0.60 | 0.88 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 84.09 | 30.78 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.